Health · Pharma & Biotech · 13 hrs ago
Cardiacto meeting discusses antibody drugs to lower LDL cholesterol
At the Cardiacto 2026 congress in Palermo, specialists discussed ways to lower LDL cholesterol.
Alberto Corsini, a professor at the University of Milan, presented the strategies.
Existing treatments remain in use, while doctors also use newer medicines called monoclonal antibodies.
Earlier studies found benefits for people at very high risk and those receiving secondary prevention.
Earlier research had not covered high-risk people without prior cardiovascular events.
The discussion drew attention to this gap, but no next steps were specified.
Alberto Corsini presented strategies to lower LDL cholesterol at the Cardiacto 2026 congress in Palermo.
He said standard clinical treatments remain in use, alongside newer medicines such as monoclonal antibodies.
Corsini said earlier studies had documented benefits for very-high-risk patients and those receiving secondary prevention.
He noted that high-risk patients without previous cardiovascular events had been missing from those studies.
- Who
- Alberto Corsini, a professor at the University of Milan.
- What
- He presented strategies to lower LDL cholesterol, including the use of monoclonal antibodies.
- When
- At the Cardiacto 2026 congress; the exact congress date is not stated.
- Where
- Palermo. One source identifies the Marina Convention Center as the venue.
- Why
- To discuss strategies for lowering LDL cholesterol and the use of newer treatments.
This story does not have two clearly opposing sides.
Studies documented benefits for very-high-risk patients and patients receiving secondary prevention.
Corsini presented LDL-lowering strategies in Palermo and noted that high-risk patients without cardiovascular events had been missing from earlier studies.
- Speaker
- Alberto Corsini
- Congress
- Cardiacto 2026
- Location
- Palermo; Marina Convention Center named by PalermoToday
- Treatments
- Monoclonal antibodies to lower LDL cholesterol
- Research gap
- High-risk patients without cardiovascular events were missing from earlier studies
3 sources
What people are saying
The therapies used in everyday clinical practice remain, but more technological drugs such as monoclonal antibodies are also used.